Skip to main content
Home
  • About Us
    • About Us
    • Mission & Values
    • Leadership
    • News
    • Careers
    • Partnerships
    • Support
    • Achievements
  • For Researchers
    • Clinical Trials
      • Allergy & Asthma
      • Autoimmune Disease
      • Transplantation
      • Type 1 Diabetes
    • Core Facilities
    • Lab Protocols
      • ITN Protocols
      • T1D Preclinical Consortium
    • Policies
      • Publications Policy
    • Proposals
      • Submit Proposal
      • Current RFPs
      • Past RFPs
    • Publications
    • TrialShare
    • Strategic Plans
      • Allergy
      • Autoimmune Disease
        • Type 1 Diabetes
      • Transplantation
  • For Patients
    • Allergy & Asthma
    • Autoimmune Disease
    • Transplantation
      • Kidney
      • Liver
    • Type 1 Diabetes
    • Clinical Trial Info
  • TrialShare
  • Contact
    • Contact Us
      • BRI - Seattle Office
      • UCSF - San Francisco Office
    • Media Inquiries
Home

Secondary links

  • Home
  • TrialShare
  • Member Portal
  • About Us
    • About Us
    • Mission & Values
    • Leadership
    • News
    • Careers
    • Partnerships
    • Support
    • Achievements
  • For Researchers
    • Clinical Trials
    • Core Facilities
    • Lab Protocols
    • Policies
    • Proposals
    • Publications
    • TrialShare
    • Strategic Plans
  • For Patients
    • Allergy & Asthma
    • Autoimmune Disease
    • Transplantation
    • Type 1 Diabetes
    • Clinical Trial Info
  • TrialShare
  • Contact
    • Contact Us
    • Media Inquiries

Primary links (clinical trials)

  • About Us
    • About Us
    • Mission & Values
    • Leadership
    • News
    • Careers
    • Partnerships
    • Support
    • Achievements
  • For Researchers
    • Clinical Trials
      • Allergy & Asthma
      • Autoimmune Disease
      • Transplantation
      • Type 1 Diabetes
    • Core Facilities
    • Lab Protocols
      • ITN Protocols
      • T1D Preclinical Consortium
    • Policies
      • Publications Policy
    • Proposals
      • Submit Proposal
      • Current RFPs
      • Past RFPs
    • Publications
    • TrialShare
    • Strategic Plans
      • Allergy
      • Autoimmune Disease
      • Transplantation
  • For Patients
    • Allergy & Asthma
    • Autoimmune Disease
    • Transplantation
      • Kidney
      • Liver
    • Type 1 Diabetes
    • Clinical Trial Info
  • TrialShare
  • Contact
    • Contact Us
      • BRI - Seattle Office
      • UCSF - San Francisco Office
    • Media Inquiries

Measuring Allospecific Impact of Belatacept/Carfilzomib Desensitization (ADAPT)

Principal Investigator

Stuart Knechtle, MD | Duke University Hospital

Locations

Duke University Hospital | Durham, NC

Study Code

ITN089ST

Study Status

Active

Abstract

ADAPT is a clinical study to learn whether a new treatment plan can increase the chances for highly sensitized kidney transplant candidates to find a kidney donor match.

Highly sensitized patients whose immune systems are much more likely to react against donated organs could have to wait a very long time to find a donor kidney that their immune system will accept.

Since plasma cells make antibodies, ADAPT will investigate whether using carfilzomib (Kyprolis®) and belatacept (Nulojix®) together can reduce the number of plasma cells in "highly sensitized" people while they are on the kidney transplant waiting list. This process is called desensitization and would improve the chances of finding a "matching" donor and reduce the risk of rejection after transplant.

Participants will have a total of 12 infusions of carfilzomib and 16 doses of belatacept. Research samples (blood, tissue, and bone marrow cells) will be collected during this study.

Study participation will last 76 weeks (18 months). If the participant receives a transplant during their time in the study, there will be extra follow up for 1 year.

Phase

# of Visits

How Long Phase Lasts

Screening and Enrollment

2 - 4

Up to 12 weeks

Study Treatment

26

52 weeks

Follow-up

1 - 9

12-51 weeks

Extra follow up if you get a transplant while in the study

15

52 weeks after transplant

About This Study

ADAPT is a clinical study to learn whether a new treatment plan can increase the chances for highly sensitized kidney transplant candidates to find a kidney donor match.

The goal of the ADAPT study is to study whether using two drugs, carfilzomib (Kyprolis®) and belatacept (Nulojix®), together can lower the number of plasma cells in “highly sensitized” people on the kidney transplant waiting list.

Highly Sensitized Kidney Transplant Recipients

Before you get a kidney transplant, doctors run tests to find out if your immune system will react against potential kidney donors. If those tests show that you are “highly sensitized,” meaning your immune system will react against the donated organs of most people (9 out of 10), then it might take a very long time to find a donor kidney that your immune system will accept. Also, having a more reactive immune system makes it more likely that your body will reject the transplant.

ADAPT and your Plasma Cells

Plasma cells are immune system cells that make antibodies. Antibodies are proteins that recognize foreign cells and signal that an immune response should occur. With fewer plasma cells, your immune system might make fewer antibodies to kidney donor cells. This could improve your chance of finding a “matching” kidney donor and reduce your risk of rejection after transplant.

We do not know whether you or anyone participating in this study will make fewer antibodies or be more likely to get a transplant.

Participating in ADAPT

The ADAPT study has 4 phases as outlined in the table below. Your visit schedule will depend on the phase of the study and how well you are doing. In total, your participation will last 78 weeks (18 months). However, if you receive a transplant during your time in the study, you will get extra follow up for 1 year. 

Phase

# of Visits

How Long Phase Lasts

Screening and Enrollment

2 - 4

Up to 12 weeks

Study Treatment

26

52 weeks

Follow-up

1 - 9

12-51 weeks

Extra follow up if you get a transplant while in the study

15

52 weeks after transplant

You must come to the study hospital for all visits. In between some visits, you may be required to have lab work that can be done at your local laboratory. During your study visits, you will generally get a brief physical exam, a review of your health and current medications, and blood tests. 

You will also have a total of 12 infusions of carfilzomib and 16 doses of belatacept. Research samples (blood, tissue, and bone marrow cells) will be collected during this study. In addition, if you have a transplant while on this study, 1-2 lymph nodes will be taken during the transplant surgery. The lymph nodes will be taken only if they are readily available.

[Clinicaltrials.gov] [Study Website]

Do you Qualify for this Clinical Trial?

You may be eligible to participate in the ATTAIN study if you:

  • Are 18 to 65 years of age 
  • Have end stage renal disease
  • Are on the wait list for a kidney transplant
  • Have a high level of antibodies in your system that react to most kidney donors

In total, your participation may last between 18 and 30 months.

Principal Investigator

Stuart Knechtle, MD | Duke University Hospital

Locations

Duke University Hospital | Durham, NC

The Immune Tolerance Network and is sponsored by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

National Institute of Allergy and Infectious Diseases

Footer

  • Home
  • Sponsors
  • Careers
  • Contact
  • Search

© 2021 Immune Tolerance Network

  • Privacy
  • Terms of Use
  • Accessibility